Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia (Endocrine, 10.1007/s12020-016-0939-0)

Abstract

In “Glucagon and insulin” section of the original publication, it was incorrectly described as “glucose showed a strong and rapid suppression of both LDLR and PCSK9 proteins”, instead of “glucagon showed a suppression of PCSK9 mRNA and protein levels”. It should be read as: “Such observation was corroborated by a study reporting how rat administered with glucagon showed a suppression of PCSK9 mRNA and protein levels, as well as a 25% reduction in SREBP-2 mRNA expression [50].”